Predicta Biosciences

Predicta Biosciences is a Cambridge, MA-based precision oncology company that integrates multi-omics and liquid biopsy diagnostics to transform the diagnosis, monitoring, and treatment of blood cancers. From a single blood draw, its GenoPredicta platform delivers whole-genome sequencing of circulating tumor cells to uncover structural variants and clonal evolution that standard tests miss, while ImmunoPredicta adds single-cell immune profiling. The company also partners with biopharma firms for biomarker discovery, patient stratification, and clinical trial acceleration.